

Stephen Yc Tong

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3505765/stephen-yc-tong-publications-by-citations.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

199 papers	3,252 citations	31 h-index	45 g-index
213 ext. papers	4,176 ext. citations	4.7 avg, IF	5.4 L-index

#	Paper	IF	Citations
199	Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction. <i>American Journal of Obstetrics and Gynecology</i> , 2016 , 214, 356.e1-356.e15	6.4	121
198	TLR7 is involved in sequence-specific sensing of single-stranded RNAs in human macrophages. <i>Journal of Immunology</i> , 2008 , 180, 2117-24	5.3	119
197	Effects of Pravastatin on Human Placenta, Endothelium, and Women With Severe Preeclampsia. <i>Hypertension</i> , 2015 , 66, 687-97; discussion 445	8.5	111
196	Proton Pump Inhibitors Decrease Soluble fms-Like Tyrosine Kinase-1 and Soluble Endoglin Secretion, Decrease Hypertension, and Rescue Endothelial Dysfunction. <i>Hypertension</i> , 2017 , 69, 457-468	8.5	84
195	Effects of maternal obstructive sleep apnoea on fetal growth: a prospective cohort study. <i>PLoS ONE</i> , 2013 , 8, e68057	3.7	72
194	Serum concentrations of macrophage inhibitory cytokine 1 (MIC 1) as a predictor of miscarriage. <i>Lancet, The</i> , 2004 , 363, 129-30	4.0	72
193	Circulating MicroRNAs in maternal blood as potential biomarkers for fetal hypoxia in-utero. <i>PLoS ONE</i> , 2013 , 8, e78487	3.7	66
192	Rational design of immunostimulatory siRNAs. <i>Molecular Therapy</i> , 2010 , 18, 785-95	11.7	59
191	Placental-Specific sFLT-1 e15a Protein Is Increased in Preeclampsia, Antagonizes Vascular Endothelial Growth Factor Signaling, and Has Antiangiogenic Activity. <i>Hypertension</i> , 2015 , 66, 1251-9	8.5	58
190	MMP-14 is expressed in preeclamptic placentas and mediates release of soluble endoglin. <i>American Journal of Pathology</i> , 2012 , 180, 888-894	5.8	56
189	Use of dizygotic to monozygotic twinning ratio as a measure of fertility. <i>Lancet, The</i> , 1997 , 349, 843-5	4.0	55
188	Parity is a major determinant of success rate in medical abortion: a retrospective analysis of 3161 consecutive cases of early medical abortion treated with reduced doses of mifepristone and vaginal gemeprost. <i>Contraception</i> , 2000 , 62, 297-303	2.5	54
187	Pre-eclampsia. <i>Lancet, The</i> , 2021 , 398, 341-354	4.0	54
186	The use of miRNA microarrays for the analysis of cancer samples with global miRNA decrease. <i>Rna</i> , 2013 , 19, 876-88	5.8	46
185	Characterization of protocols for primary trophoblast purification, optimized for functional investigation of sFlt-1 and soluble endoglin. <i>Pregnancy Hypertension</i> , 2014 , 4, 287-95	2.6	45
184	Placental-specific sFLT-1: role in pre-eclamptic pathophysiology and its translational possibilities for clinical prediction and diagnosis. <i>Molecular Human Reproduction</i> , 2017 , 23, 69-78	4.4	44
183	Placental specific mRNA in the maternal circulation are globally dysregulated in pregnancies complicated by fetal growth restriction. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, E429-36	5.6	43

182	Paternal obesity in a rodent model affects placental gene expression in a sex-specific manner. <i>Reproduction</i> , 2015 , 149, 435-44	3.8	42
181	Enoxaparin for the prevention of preeclampsia and intrauterine growth restriction in women with a history of a randomized trial. <i>American Journal of Obstetrics and Gynecology</i> , 2017 , 216, 296.e1-296.e14	6.4	41
180	Resveratrol inhibits release of soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin and improves vascular dysfunction - implications as a preeclampsia treatment. <i>Scientific Reports</i> , 2017 , 7, 1819	4.9	39
179	Esomeprazole to treat women with preterm preeclampsia: a randomized placebo controlled trial. <i>American Journal of Obstetrics and Gynecology</i> , 2018 , 219, 388.e1-388.e17	6.4	39
178	Predicting perinatal outcome through changes in umbilical artery Doppler studies after antenatal corticosteroids in the growth-restricted fetus. <i>Obstetrics and Gynecology</i> , 2009 , 113, 636-640	4.9	39
177	Sofalcone upregulates the nuclear factor (erythroid-derived 2)-like 2/heme oxygenase-1 pathway, reduces soluble fms-like tyrosine kinase-1, and quenches endothelial dysfunction: potential therapeutic for preeclampsia. <i>Hypertension</i> , 2015 , 65, 855-62	8.5	38
176	Reduced growth velocity across the third trimester is associated with placental insufficiency in fetuses born at a normal birthweight: a prospective cohort study. <i>BMC Medicine</i> , 2017 , 15, 164	11.4	37
175	Measurement of mRNA transcripts of very high placental expression in maternal blood as biomarkers of preeclampsia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, E1807-15	5.6	35
174	Characterization of symptoms immediately preceding eclampsia. <i>Obstetrics and Gynecology</i> , 2011 , 118, 995-999	4.9	34
173	Effects of simvastatin, rosuvastatin and pravastatin on soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG) secretion from human umbilical vein endothelial cells, primary trophoblast cells and placenta. <i>BMC Pregnancy and Childbirth</i> , 2016 , 16, 117	3.2	32
172	Soluble endoglin production is upregulated by oxysterols but not quenched by pravastatin in primary placental and endothelial cells. <i>Placenta</i> , 2014 , 35, 724-31	3.4	32
171	Is fetal growth restriction associated with a more severe maternal phenotype in the setting of early onset pre-eclampsia? A retrospective study. <i>PLoS ONE</i> , 2011 , 6, e26937	3.7	32
170	Targeted nanoparticle delivery of doxorubicin into placental tissues to treat ectopic pregnancies. <i>Endocrinology</i> , 2013 , 154, 911-9	4.8	31
169	Placental Insufficiency in Fetuses That Slow in Growth but Are Born Appropriate for Gestational Age: A Prospective Longitudinal Study. <i>PLoS ONE</i> , 2016 , 11, e0142788	3.7	31
168	The evolution of methotrexate as a treatment for ectopic pregnancy and gestational trophoblastic neoplasia: a review. <i>ISRN Obstetrics & Gynecology</i> , 2012 , 2012, 637094		30
167	Placental expression of a novel primate-specific splice variant of sFlt-1 is upregulated in pregnancies complicated by severe early onset pre-eclampsia. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2011 , 118, 1268-71	3.7	29
166	PAPPA2 is increased in severe early onset pre-eclampsia and upregulated with hypoxia. <i>Reproduction, Fertility and Development</i> , 2014 , 26, 351-7	1.8	28
165	Double blind, randomised, placebo-controlled trial to evaluate the efficacy of esomeprazole to treat early onset pre-eclampsia (PIE Trial): a study protocol. <i>BMJ Open</i> , 2015 , 5, e008211	3	28

164	Placental HtrA3 is regulated by oxygen tension and serum levels are altered during early pregnancy in women destined to develop preeclampsia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, 403-11	5.6	28
163	Miscarriage risk for asymptomatic women after a normal first-trimester prenatal visit. <i>Obstetrics and Gynecology</i> , 2008 , 111, 710-4	4.9	28
162	Human HtrA4 Expression Is Restricted to the Placenta, Is Significantly Up-Regulated in Early-Onset Preeclampsia, and High Levels of HtrA4 Cause Endothelial Dysfunction. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, E936-45	5.6	27
161	EGFR (Epidermal Growth Factor Receptor) Signaling and the Mitochondria Regulate sFlt-1 (Soluble FMS-Like Tyrosine Kinase-1) Secretion. <i>Hypertension</i> , 2019 , 73, 659-670	8.5	27
160	Diagnostic accuracy of maternal serum macrophage inhibitory cytokine-1 and pregnancy-associated plasma protein-A at 6-10 weeks of gestation to predict miscarriage. <i>Obstetrics and Gynecology</i> , 2012 , 119, 1000-8	4.9	26
159	ELABELA/APELA Levels Are Not Decreased in the Maternal Circulation or Placenta among Women with Preeclampsia. <i>American Journal of Pathology</i> , 2018 , 188, 1749-1753	5.8	26
158	A double blind, randomised, placebo-controlled trial to evaluate the efficacy of metformin to treat preterm pre-eclampsia (PI2 Trial): study protocol. <i>BMJ Open</i> , 2019 , 9, e025809	3	25
157	Combining metformin and esomeprazole is additive in reducing sFlt-1 secretion and decreasing endothelial dysfunction - implications for treating preeclampsia. <i>PLoS ONE</i> , 2018 , 13, e0188845	3.7	25
156	The role of leukemia inhibitory factor in tubal ectopic pregnancy. <i>Placenta</i> , 2013 , 34, 1014-9	3.4	25
155	Association between maternal serum cytokine profiles at 7-10 weeks gestation and birthweight in small for gestational age infants. <i>American Journal of Obstetrics and Gynecology</i> , 2011 , 204, 415.e1-415.e12	6.4	25
154	Heme Oxygenase-1 Is Not Decreased in Preeclamptic Placenta and Does Not Negatively Regulate Placental Soluble fms-Like Tyrosine Kinase-1 or Soluble Endoglin Secretion. <i>Hypertension</i> , 2015 , 66, 1073-81	8.5	24
153	Severe early-onset preeclampsia is not associated with a change in placental catechol O-methyltransferase (COMT) expression. <i>American Journal of Pathology</i> , 2011 , 178, 2484-8	5.8	24
152	Inhibins and activins: clinical advances in reproductive medicine. <i>Clinical Endocrinology</i> , 2003 , 58, 115-27	3.4	24
151	YC-1 reduces placental sFlt-1 and soluble endoglin production and decreases endothelial dysfunction: A possible therapeutic for preeclampsia. <i>Molecular and Cellular Endocrinology</i> , 2015 , 413, 202-8	4.4	23
150	Measuring circulating placental RNAs to non-invasively assess the placental transcriptome and to predict pregnancy complications. <i>Prenatal Diagnosis</i> , 2016 , 36, 997-1008	3.2	23
149	Melatonin enhances antioxidant molecules in the placenta, reduces secretion of soluble fms-like tyrosine kinase 1 (sFLT) from primary trophoblast but does not rescue endothelial dysfunction: An evaluation of its potential to treat preeclampsia. <i>PLoS ONE</i> , 2018 , 13, e0187082	3.7	23
148	Using a decline in serum hCG between days 0-4 to predict ectopic pregnancy treatment success after single-dose methotrexate: a retrospective cohort study. <i>BMC Pregnancy and Childbirth</i> , 2013 , 13, 30	3.2	23
147	Corin, an enzyme with a putative role in spiral artery remodeling, is up-regulated in late secretory endometrium and first trimester decidua. <i>Human Reproduction</i> , 2013 , 28, 1172-80	5.7	23

146	Decline in BCG levels between days 0 and 4 after a single dose of methotrexate for ectopic pregnancy predicts treatment success: a retrospective cohort study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2011 , 118, 1665-8	3.7	23
145	The circulating microRNA-200 family in whole blood are potential biomarkers for high-grade serous epithelial ovarian cancer. <i>Biomedical Reports</i> , 2017 , 6, 319-322	1.8	22
144	Sulfasalazine reduces placental secretion of antiangiogenic factors, up-regulates the secretion of placental growth factor and rescues endothelial dysfunction. <i>EBioMedicine</i> , 2019 , 41, 636-648	8.8	22
143	Quantifying circulating hypoxia-induced RNA transcripts in maternal blood to determine in utero fetal hypoxic status. <i>BMC Medicine</i> , 2013 , 11, 256	11.4	20
142	Maternal serum interleukin-33 and soluble ST2 across early pregnancy, and their association with miscarriage. <i>Journal of Reproductive Immunology</i> , 2012 , 95, 46-9	4.2	19
141	Combination gefitinib and methotrexate compared with methotrexate alone to treat ectopic pregnancy. <i>Obstetrics and Gynecology</i> , 2013 , 122, 745-751	4.9	19
140	Pravastatin, proton-pump inhibitors, metformin, micronutrients, and biologics: new horizons for the prevention or treatment of preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , 2020 ,	6.4	19
139	Circulating SPINT1 is a biomarker of pregnancies with poor placental function and fetal growth restriction. <i>Nature Communications</i> , 2020 , 11, 2411	17.4	18
138	Galectin-7 acts as an adhesion molecule during implantation and increased expression is associated with miscarriage. <i>Placenta</i> , 2014 , 35, 195-201	3.4	18
137	Treatment of early-onset preeclampsia with continuous positive airway pressure. <i>Obstetrics and Gynecology</i> , 2015 , 125, 1106-1109	4.9	18
136	Cord blood sampling at delivery: do we need to always collect from both vessels?. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2002 , 109, 1175-7	3.7	18
135	Identifying late-onset fetal growth restriction by measuring circulating placental RNA in the maternal blood at 28 weeks gestation. <i>American Journal of Obstetrics and Gynecology</i> , 2016 , 214, 521.e1-521.e8	6.4	17
134	Effects of gefitinib, an epidermal growth factor receptor inhibitor, on human placental cell growth. <i>Obstetrics and Gynecology</i> , 2013 , 122, 737-744	4.9	17
133	First trimester levels of inhibins and activin A in normal and failing pregnancies. <i>Clinical Endocrinology</i> , 2004 , 60, 484-90	3.4	17
132	Low levels of pregnancy-associated plasma protein-A in asymptomatic women destined for miscarriage. <i>Fertility and Sterility</i> , 2004 , 82, 1468-70	4.8	17
131	Activating Transcription Factor 3 Is Reduced in Preeclamptic Placentas and Negatively Regulates sFlt-1 (Soluble fms-Like Tyrosine Kinase 1), Soluble Endoglin, and Proinflammatory Cytokines in Placenta. <i>Hypertension</i> , 2017 , 70, 1014-1024	8.5	16
130	Stability of absolute copy number of housekeeping genes in preeclamptic and normal placentas, as measured by digital PCR. <i>Placenta</i> , 2014 , 35, 1106-9	3.4	16
129	MT-MMPs in pre-eclamptic placenta: relationship to soluble endoglin production. <i>Placenta</i> , 2013 , 34, 168-73	3.4	16

128	Circulating RNA coding genes regulating apoptosis in maternal blood in severe early onset fetal growth restriction and pre-eclampsia. <i>Journal of Perinatology</i> , 2013 , 33, 600-4	3.1	16
127	Aspirin use during pregnancy and the risk of bleeding complications: a Swedish population-based cohort study. <i>American Journal of Obstetrics and Gynecology</i> , 2021 , 224, 95.e1-95.e12	6.4	16
126	Proton Pump Inhibitors and Preeclampsia Risk Among 157 720 Women. <i>Hypertension</i> , 2019 , 73, 1097-1103	3.5	15
125	Pravastatin as the statin of choice for reducing pre-eclampsia-associated endothelial dysfunction. <i>Pregnancy Hypertension</i> , 2020 , 20, 83-91	2.6	15
124	Assessing the sensitivity of placental growth factor and soluble fms-like tyrosine kinase 1 at 36 weeks gestation to predict small-for-gestational-age infants or late-onset preeclampsia: a prospective nested case-control study. <i>BMC Pregnancy and Childbirth</i> , 2018 , 18, 354	3.2	15
123	Molecular diagnostics and therapeutics for ectopic pregnancy. <i>Molecular Human Reproduction</i> , 2015 , 21, 126-35	4.4	14
122	Jumonji Domain Containing Protein 6 Is Decreased in Human Preeclamptic Placentas and Regulates sFLT-1 Splice Variant Production. <i>Biology of Reproduction</i> , 2016 , 94, 59	3.9	14
121	Chorioamnionitis Occurring in Women With Preterm Rupture of the Fetal Membranes Is Associated With a Dynamic Increase in mRNAs Coding Cytokines in the Maternal Circulation. <i>Reproductive Sciences</i> , 2015 , 22, 852-9	3	14
120	MMP-15 is upregulated in preeclampsia, but does not cleave endoglin to produce soluble endoglin. <i>PLoS ONE</i> , 2012 , 7, e39864	3.7	14
119	Quantifying mRNA coding growth genes in the maternal circulation to detect fetal growth restriction. <i>American Journal of Obstetrics and Gynecology</i> , 2013 , 209, 133.e1-9	6.4	14
118	Thyroid function and autoantibody status among women who spontaneously deliver under 35 weeks of gestation. <i>Clinical Endocrinology</i> , 2009 , 71, 892-5	3.4	14
117	Serum concentrations of soluble Flt-1 are decreased among women with a viable fetus and no symptoms of miscarriage destined for pregnancy loss. <i>PLoS ONE</i> , 2012 , 7, e32509	3.7	14
116	Plasma MIC-1 and PAPP-a levels are decreased among women presenting to an early pregnancy assessment unit, have fetal viability confirmed but later miscarry. <i>PLoS ONE</i> , 2013 , 8, e72437	3.7	14
115	The untapped potential of placenta-enriched molecules for diagnostic and therapeutic development. <i>Placenta</i> , 2019 , 84, 28-31	3.4	14
114	Corpus luteum across the first trimester: size and laterality as observed by ultrasound. <i>Fertility and Sterility</i> , 2008 , 90, 1844-7	4.8	13
113	Circulating mRNAs are differentially expressed in pregnancies with severe placental insufficiency and at high risk of stillbirth. <i>BMC Medicine</i> , 2020 , 18, 145	11.4	13
112	A bioplex analysis of cytokines and chemokines in first trimester maternal plasma to screen for predictors of miscarriage. <i>PLoS ONE</i> , 2014 , 9, e93320	3.7	12
111	ATF3 is a negative regulator of inflammation in human fetal membranes. <i>Placenta</i> , 2016 , 47, 63-72	3.4	12

110	Maternal plasma concentrations of the placental specific sFLT-1 variant, sFLT-1 e15a, in fetal growth restriction and preeclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2017 , 30, 635-639 ²		11
109	Key players of the necroptosis pathway RIPK1 and SIRT2 are altered in placenta from preeclampsia and fetal growth restriction. <i>Placenta</i> , 2017 , 51, 1-9	3.4	11
108	Epidermal Growth Factor Rescues Endothelial Dysfunction in Primary Human Tissues In Vitro. <i>Reproductive Sciences</i> , 2017 , 24, 1245-1252	3	11
107	Measuring hypoxia-induced RNA in maternal blood: a new way to identify critically hypoxic fetuses in utero?. <i>Expert Review of Molecular Diagnostics</i> , 2014 , 14, 509-11	3.8	11
106	Determining zygosity in early pregnancy by ultrasound. <i>Ultrasound in Obstetrics and Gynecology</i> , 2004 , 23, 36-7	5.8	11
105	Combination gefitinib and methotrexate treatment for non-tubal ectopic pregnancies: a case series. <i>Human Reproduction</i> , 2014 , 29, 1375-9	5.7	10
104	Evaluation of ADAM-12 as a diagnostic biomarker of ectopic pregnancy in women with a pregnancy of unknown location. <i>PLoS ONE</i> , 2012 , 7, e41442	3.7	10
103	Impairment of Angiogenic Sphingosine Kinase-1/Sphingosine-1-Phosphate Receptors Pathway in Preeclampsia. <i>PLoS ONE</i> , 2016 , 11, e0157221	3.7	10
102	Novel approaches to combat preeclampsia: from new drugs to innovative delivery. <i>Placenta</i> , 2020 , 102, 10-16	3.4	10
101	Nanoparticles in pregnancy: the next frontier in reproductive therapeutics. <i>Human Reproduction Update</i> , 2021 , 27, 280-304	15.8	10
100	Association between low day 16 hCG and miscarriage after proven cardiac activity. <i>Obstetrics and Gynecology</i> , 2006 , 107, 300-4	4.9	9
99	Maternal serum activin A and the prediction of intrauterine growth restriction. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2006 , 46, 97-101	1.7	9
98	Sonography: dizygotic twin survival in early pregnancy. <i>Nature</i> , 2002 , 416, 142	50.4	9
97	Predictive Value of the Signs and Symptoms Preceding Eclampsia: A Systematic Review. <i>Obstetrics and Gynecology</i> , 2019 , 134, 677-684	4.9	9
96	Transcription factors E2F1 and E2F3 are expressed in placenta but do not regulate MMP14. <i>Placenta</i> , 2015 , 36, 932-7	3.4	8
95	PLAC4 is upregulated in severe early onset preeclampsia and upregulated with syncytialisation but not hypoxia. <i>Placenta</i> , 2013 , 34, 256-60	3.4	8
94	Has increased clinical experience with methotrexate reduced the direct costs of medical management of ectopic pregnancy compared to surgery?. <i>BMC Pregnancy and Childbirth</i> , 2012 , 12, 98	3.2	8
93	Phase II single arm open label multicentre clinical trial to evaluate the efficacy and side effects of a combination of gefitinib and methotrexate to treat tubal ectopic pregnancies (GEM II): study protocol. <i>BMJ Open</i> , 2013 , 3,	3	8

92	Maternal and foetal activin A levels: associations with normal and abnormal labour. <i>Placenta</i> , 2002 , 23, 570-4	3.4	8
91	Use of metformin to prolong gestation in preterm pre-eclampsia: randomised, double blind, placebo controlled trial. <i>BMJ, The</i> , 2021 , 374, n2103	5.9	8
90	Combining metformin and sulfasalazine additively reduces the secretion of antiangiogenic factors from the placenta: Implications for the treatment of preeclampsia. <i>Placenta</i> , 2020 , 95, 78-83	3.4	7
89	Nuclear factor of activated T-cells (NFAT) regulates soluble fms-like tyrosine kinase-1 secretion (sFlt-1) from human placenta. <i>Placenta</i> , 2016 , 48, 110-118	3.4	7
88	Of leaves and butterflies: how methotrexate came to be the savior of women. <i>Obstetrics and Gynecology</i> , 2011 , 118, 1169-1173	4.9	7
87	Steroid sulfatase is increased in the placentas and whole blood of women with early-onset preeclampsia. <i>Placenta</i> , 2016 , 48, 72-79	3.4	7
86	Death associated protein kinase 1 (DAPK-1) is increased in preeclampsia. <i>Placenta</i> , 2019 , 88, 1-7	3.4	6
85	Circulating adrenomedullin mRNA is decreased in women destined to develop term preeclampsia. <i>Pregnancy Hypertension</i> , 2019 , 16, 16-25	2.6	6
84	Circulating Delta-like homolog 1 (DLK1) at 36 weeks is correlated with birthweight and is of placental origin. <i>Placenta</i> , 2020 , 91, 24-30	3.4	6
83	Loss of Akt increases soluble endoglin release from endothelial cells but not placenta. <i>Pregnancy Hypertension</i> , 2016 , 6, 95-102	2.6	6
82	Blood-based biomarkers in the maternal circulation associated with fetal growth restriction. <i>Prenatal Diagnosis</i> , 2019 , 39, 947-957	3.2	6
81	sFlt-1 and soluble endoglin concentrations in serum vs plasma in preterm preeclampsia: Are they interchangeable for biomarker studies?. <i>Pregnancy Hypertension</i> , 2017 , 10, 18-21	2.6	6
80	Reduced growth velocity from the mid-trimester is associated with placental insufficiency in fetuses born at a normal birthweight. <i>BMC Medicine</i> , 2020 , 18, 395	11.4	6
79	Clinical tools and biomarkers to predict preeclampsia.. <i>EBioMedicine</i> , 2021 , 75, 103780	8.8	6
78	MicroRNAs 363 and 149 are differentially expressed in the maternal circulation preceding a diagnosis of preeclampsia. <i>Scientific Reports</i> , 2020 , 10, 18077	4.9	6
77	Effect of sildenafil citrate on circulating levels of sFlt-1 in preeclampsia. <i>Pregnancy Hypertension</i> , 2018 , 13, 1-6	2.6	5
76	Prediction of adverse maternal outcomes in preeclampsia at term. <i>Pregnancy Hypertension</i> , 2019 , 18, 75-81	2.6	5
75	Placental SEMA3B expression is not altered in severe early onset preeclampsia. <i>Placenta</i> , 2014 , 35, 1102-1105	3.4	5

74	Association between twin discordance at 6-9 weeks of gestation and birthweight complications. <i>Twin Research and Human Genetics</i> , 2010 , 13, 389-92	2.2	5
73	Fetal activin A: associations with labour, umbilical artery pH and neonatal outcome. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2004 , 111, 326-30	3.7	5
72	Delayed presentation of uterine perforation and haemorrhagic shock 10 days after surgical termination of pregnancy. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2001 , 41, 335-6	1.7	5
71	Esomeprazole and sulfasalazine in combination additively reduce sFlt-1 secretion and diminish endothelial dysfunction: potential for a combination treatment for preeclampsia. <i>Pregnancy Hypertension</i> , 2020 , 22, 86-92	2.6	5
70	Circulating Tissue Factor Pathway Inhibitor (TFPI) is increased preceding preeclampsia diagnosis and in established preeclampsia. <i>Placenta</i> , 2021 , 105, 32-40	3.4	5
69	Sulfasalazine decreases soluble fms-like tyrosine kinase-1 secretion potentially via inhibition of upstream placental epidermal growth factor receptor signalling. <i>Placenta</i> , 2019 , 87, 53-57	3.4	4
68	Circulating GATA2 mRNA is decreased among women destined to develop preeclampsia and may be of endothelial origin. <i>Scientific Reports</i> , 2019 , 9, 235	4.9	4
67	Expectant management of severe preterm preeclampsia: a comparison of maternal and fetal indications for delivery. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2016 , 29, 3821-6	2	4
66	Systematic review of areca (betel nut) use and adverse pregnancy outcomes. <i>International Journal of Gynecology and Obstetrics</i> , 2019 , 147, 292-300	4	4
65	Measuring thyroid peroxidase antibodies on the day nulliparous women present for management of miscarriage: a descriptive cohort study. <i>Reproductive Biology and Endocrinology</i> , 2013 , 11, 40	5	4
64	Hysteroscopy under general anaesthesia, a near painless procedure. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2003 , 43, 344-5	1.7	4
63	Maternal Serum Macrophage Inhibitory Cytokine-1 as a Biomarker for Ectopic Pregnancy in Women with a Pregnancy of Unknown Location. <i>PLoS ONE</i> , 2013 , 8, e66339	3.7	4
62	Appropriate-for-gestational-age infants who exhibit reduced antenatal growth velocity display postnatal catch-up growth. <i>PLoS ONE</i> , 2020 , 15, e0238700	3.7	4
61	Maternal circulating SPINT1 is reduced in small-for-gestational age pregnancies at 26 weeks: Growing up in Singapore towards health outcomes (GUSTO) cohort study. <i>Placenta</i> , 2021 , 110, 24-28	3.4	4
60	The incidence of hypertensive disorders of pregnancy following sperm donation in IVF: an Australian state-wide retrospective cohort study. <i>Human Reproduction</i> , 2019 , 34, 2541-2548	5.7	4
59	High-dose compared with low-dose oxytocin for induction of labour of nulliparous women at term. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2019 , 32, 362-368	2	4
58	EGFL7 gene expression is regulated by hypoxia in trophoblast and altered in the plasma of patients with early preeclampsia. <i>Pregnancy Hypertension</i> , 2018 , 14, 115-120	2.6	4
57	Circulating Growth Differentiation Factor 15 Is Increased Preceding Preeclampsia Diagnosis: Implications as a Disease Biomarker. <i>Journal of the American Heart Association</i> , 2021 , 10, e020302	6	4

56	Vinorelbine Potently Induces Placental Cell Death, Does Not Harm Fertility and is a Potential Treatment for Ectopic Pregnancy. <i>EBioMedicine</i> , 2018 , 29, 166-176	8.8	3
55	Two corpora lutea seen at 6-13 weeksRgestation infers dizygosity among spontaneous same-sexed dichorionic twins. <i>Twin Research and Human Genetics</i> , 2009 , 12, 180-2	2.2	3
54	Ultrasound Reference Chart Based on IVF Dates to Estimate Gestational Age at 6-9 weeksR Gestation. <i>ISRN Obstetrics & Gynecology</i> , 2012 , 2012, 938583		3
53	Activin A, hypoxia and the prediction of obstetric outcomes. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2006 , 46, 146-7	1.7	3
52	Maternal serum and amniotic fluid levels of macrophage inhibitory cytokine 1 in Down syndrome and chromosomally normal pregnancies. <i>Prenatal Diagnosis</i> , 2004 , 24, 224-6	3.2	3
51	Elevated Circulating and Placental SPINT2 Is Associated with Placental Dysfunction. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
50	Maternal mortality at the National Referral Hospital in Honiara, Solomon Islands over a five-year period. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2020 , 60, 183-187	1.7	3
49	Gefitinib and Methotrexate to Treat Ectopic Pregnancies with a Pre-Treatment Serum hCG 1000-10,000 IU/L: Phase II Open Label, Single Arm Multi-Centre Trial. <i>EBioMedicine</i> , 2018 , 33, 276-281	8.8	3
48	Aurora kinase mRNA expression is reduced with increasing gestational age and in severe early onset fetal growth restriction. <i>Placenta</i> , 2020 , 95, 53-61	3.4	2
47	Accelerated fetal growth velocity across the third trimester is associated with increased shoulder dystocia risk among fetuses who are not large-for-gestational-age: A prospective observational cohort study. <i>PLoS ONE</i> , 2021 , 16, e0258634	3.7	2
46	DAAM2 is elevated in the circulation and placenta in pregnancies complicated by fetal growth restriction and is regulated by hypoxia. <i>Scientific Reports</i> , 2021 , 11, 5540	4.9	2
45	A comparison of sample collection methods for quantifying cell-free fetal neurodevelopment transcripts in amniotic fluid. <i>BMC Research Notes</i> , 2016 , 9, 335	2.3	2
44	Prognostic value of human chorionic gonadotropin levels 4 days after a single dose of methotrexate for ectopic pregnancy. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2012 , 119, 506-507	3.7	1
43	Highly specific and sensitive rise in Days 14-17 pro-alphaC inhibin with clinical pregnancy after frozen embryo transfer with ovulatory cycles. <i>Human Reproduction</i> , 2007 , 22, 2249-53	5.7	1
42	Increased day 15-17 serum pro-alphaC inhibin levels specific to successful pregnancy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 4464-8	5.6	1
41	Estimation of neonatal body fat percentage predicts neonatal hypothermia better than birthweight centile.. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2022 , 1-8	2	1
40	Dizygotic to monozygotic twinning ratio at The Royal Women's Hospital, Melbourne 1947-1997, compared with Australian national twinning incidence. <i>Twin Research and Human Genetics</i> , 2000 , 3, 12-6		1
39	Leather, oranges, dead pigs and needlestick injuries. <i>Medical Journal of Australia</i> , 1996 , 165, 683	4	1

38	A Systematic Review of Proton Pump Inhibitors for the Prevention and Treatment of Preeclampsia and Gestational Hypertension. <i>Open Journal of Obstetrics and Gynecology</i> , 2019 , 09, 21-28	0.1	1
37	A disintegrin and metalloproteinase 12 (ADAM12) is reduced at 36 weeksRgestation in pregnancies destined to deliver small for gestational age infants. <i>Placenta</i> , 2021 , 117, 1-4	3.4	1
36	Nicotinamide and its effects on endothelial dysfunction and secretion of antiangiogenic factors by primary human placental cells and tissues. <i>Placenta</i> , 2021 , 109, 28-31	3.4	1
35	Pre-Clinical Investigation of Cardioprotective Beta-Blockers as a Therapeutic Strategy for Preeclampsia. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
34	Circulating syndecan-1 is reduced in pregnancies with poor fetal growth and its secretion regulated by matrix metalloproteinases and the mitochondria. <i>Scientific Reports</i> , 2021 , 11, 16595	4.9	1
33	LOX-1 expression is reduced in placenta from pregnancies complicated by preeclampsia and in hypoxic cytotrophoblast. <i>Pregnancy Hypertension</i> , 2021 , 25, 255-261	2.6	1
32	PSG7 and 9 (Pregnancy-Specific B Glycoproteins 7 and 9): Novel Biomarkers for Preeclampsia.. <i>Journal of the American Heart Association</i> , 2022 , e024536	6	1
31	Time to resolution of tubal ectopic pregnancy following methotrexate treatment: A retrospective cohort study. <i>PLoS ONE</i> , 2022 , 17, e0268741	3.7	1
30	Variable effect of maternal oral glucose load on circulating cell-free placental mRNAs. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2017 , 30, 501-503	2	0
29	Preventable stillbirths in the Solomon Islands - A hidden tragedy. <i>The Lancet Regional Health - Western Pacific</i> , 2020 , 5, 100050	5	0
28	Circulating Activin A is elevated at 36 weeksRgestation preceding a diagnosis of preeclampsia. <i>Pregnancy Hypertension</i> , 2021 , 27, 23-26	2.6	0
27	Transcriptomic analysis of patient plasma reveals circulating miR200c as a potential biomarker for high-grade serous ovarian cancer.. <i>Gynecologic Oncology Reports</i> , 2022 , 39, 100894	1.3	0
26	Combination methotrexate and gefitinib: A potential medical treatment for inoperable nontubal ectopic pregnancy. <i>Journal of Obstetrics and Gynaecology Research</i> , 2020 , 46, 531-535	1.9	0
25	Aspirin to prevent pre-eclampsia. <i>Drug and Therapeutics Bulletin</i> , 2021 , 59, 56-59	0.9	0
24	Risk of major labour-related complications for pregnancies progressing to 42 weeks or beyond. <i>BMC Medicine</i> , 2021 , 19, 126	11.4	0
23	A multi-centre, double-blind, placebo-controlled, randomised trial of combination methotrexate and gefitinib versus methotrexate alone to treat tubal ectopic pregnancies (GEM3): trial protocol. <i>Trials</i> , 2018 , 19, 643	2.8	0
22	Disulfiram inhibits placental soluble FMS-like tyrosine kinase-1 and soluble endoglin secretion independent of the proteasome. <i>Pregnancy Hypertension</i> , 2018 , 14, 125-130	2.6	0
21	Revisiting blood pressure thresholds to define hypertension during pregnancy: is 140/90 mmHg too high?. <i>The Lancet Global Health</i> , 2021 , 9, e1041-e1042	13.6	0

20	Severe maternal morbidity in the Asia Pacific: a systematic review and meta-analysis. <i>The Lancet Regional Health - Western Pacific</i> , 2021 , 14, 100217	5	○
19	Placental growth factor is negatively regulated by epidermal growth factor receptor (EGFR) signaling. <i>Placenta</i> , 2021 , 114, 22-28	3.4	○
18	Circulating SPINT1 in the second trimester is reduced among pregnancies that ends in low birthweight neonates: cohort study of 2006 pregnancies.. <i>American Journal of Obstetrics & Gynecology MFM</i> , 2022 , 100618	7.4	○
17	Maternal factors during pregnancy influencing maternal, fetal and childhood outcomes: Meet the Guest Editors.. <i>BMC Medicine</i> , 2022 , 20, 114	11.4	○
16	Reply. <i>American Journal of Obstetrics and Gynecology</i> , 2017 , 217, 383-384	6.4	
15	Screening circulating proteins to identify biomarkers of fetal macrosomia. <i>BMC Research Notes</i> , 2019 , 12, 587	2.3	
14	Accuracy of clinical suspicion of growth restriction at term despite a normal growth ultrasound: A retrospective cohort study. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2020 , 60, 568-573	1.7	
13	A wash step at collection of placental biopsies from preeclamptic pregnancies does not adversely affect levels of sFlt-1 or endoglin. <i>Pregnancy Hypertension</i> , 2015 , 5, 294-7	2.6	
12	Peptides do not prevent cleavage of endoglin to produce soluble endoglin. <i>Pregnancy Hypertension</i> , 2014 , 4, 255-8	2.6	
11	Author reply to letter from Dr Kafali. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2004 , 44, 172-172	1.7	
10	Dizygotic to monozygotic twinning ratio at The Royal Women's Hospital, Melbourne 1947-1997, compared with Australian national twinning incidence. <i>Twin Research and Human Genetics</i> , 2000 , 3, 12-16		
9	NR4A2 expression is not altered in placentas from cases of growth restriction or preeclampsia, but is reduced in hypoxic cytotrophoblast. <i>Scientific Reports</i> , 2021 , 11, 20670	4.9	
8	Reply. <i>American Journal of Obstetrics and Gynecology</i> , 2019 , 220, 207	6.4	
7	Measuring circulating miRNAs in early pregnancy could identify fetuses destined to undergrow and be at increased risk of stillbirth. <i>EBioMedicine</i> , 2021 , 63, 103172	8.8	
6	Appropriate-for-gestational-age infants who exhibit reduced antenatal growth velocity display postnatal catch-up growth 2020 , 15, e0238700		
5	Appropriate-for-gestational-age infants who exhibit reduced antenatal growth velocity display postnatal catch-up growth 2020 , 15, e0238700		
4	Appropriate-for-gestational-age infants who exhibit reduced antenatal growth velocity display postnatal catch-up growth 2020 , 15, e0238700		
3	Appropriate-for-gestational-age infants who exhibit reduced antenatal growth velocity display postnatal catch-up growth 2020 , 15, e0238700		

2

Appropriate-for-gestational-age infants who exhibit reduced antenatal growth velocity display postnatal catch-up growth **2020**, 15, e0238700

1

Appropriate-for-gestational-age infants who exhibit reduced antenatal growth velocity display postnatal catch-up growth **2020**, 15, e0238700